This company has been acquired
MRVF.F Stock Overview
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nuvo Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.98 |
| 52 Week High | CA$1.25 |
| 52 Week Low | CA$0.42 |
| Beta | 0.78 |
| 1 Month Change | -0.55% |
| 3 Month Change | 114.19% |
| 1 Year Change | -7.59% |
| 3 Year Change | 120.81% |
| 5 Year Change | -66.80% |
| Change since IPO | -78.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRVF.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.4% | 1.7% |
| 1Y | -7.6% | 14.9% | 26.0% |
Return vs Industry: MRVF.F underperformed the US Pharmaceuticals industry which returned -5.1% over the past year.
Return vs Market: MRVF.F exceeded the US Market which returned -13.7% over the past year.
Price Volatility
| MRVF.F volatility | |
|---|---|
| MRVF.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MRVF.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MRVF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 101 | Jesse Ledger | www.miravohealthcare.com |
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations.
Nuvo Pharmaceuticals Inc. Fundamentals Summary
| MRVF.F fundamental statistics | |
|---|---|
| Market cap | US$11.21m |
| Earnings (TTM) | US$11.06m |
| Revenue (TTM) | US$52.78m |
1.0x
P/E Ratio0.2x
P/S RatioIs MRVF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVF.F income statement (TTM) | |
|---|---|
| Revenue | CA$72.42m |
| Cost of Revenue | CA$27.36m |
| Gross Profit | CA$45.06m |
| Other Expenses | CA$29.89m |
| Earnings | CA$15.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 62.22% |
| Net Profit Margin | 20.95% |
| Debt/Equity Ratio | 1,149.7% |
How did MRVF.F perform over the long term?
See historical performance and comparison